Aeterna Zentaris, Inc. (USA) (NASDAQ:AEZS)

CAPS Rating: 4 out of 5

A growing global biopharmaceutical company focused on endrocrine therapy and oncology, in drug discovery, development and commercialization.

Recs

0
Player Avatar HedgieTown (< 20) Submitted: 5/2/2011 5:04:47 PM : Outperform Start Price: $2.33 AEZS Score: -76.23

Gotta love their pipeline.

Report this Post Reply

Featured Broker Partners


Advertisement